Codexis

Historical price data

Codexis is a mission-driven biotech company that engineers custom enzymes to enable more efficient, sustainable, and scalable manufacturing of pharmaceuticals and RNA therapeutics. Its core achievements include powering the synthesis of blockbuster drugs like sitagliptin (Januvia®), rapidly scaling an enzyme for Pfizer's Paxlovid, and launching a next-generation enzymatic RNA manufacturing platform. The company's strategy is partner-centric, focusing on providing its proprietary CodeEvolver® and ECO Synthesis® platforms as enabling technologies to biopharma companies, thereby de-risking and accelerating their development pipelines without developing its own drug assets.

Proprietary CodeEvolver® platform uses computational design and machine learning to engineer custom enzymes, and the ECO Synthesis® platform applies enzymatic ligation for scalable, sustainable RNA manufacturing.

Codexis competes in pharma biocatalysis against specialized enzyme firms and large pharma's internal teams. In RNA manufacturing, it challenges the dominant solid-phase synthesis method and emerging enzymatic approaches. Its core advantage is its deep, cross-platform enzyme engineering expertise.